ECM-modifying enzymes like lysyl oxidases are regarded as key drivers of fibrotic remodeling and are therefore considered attractive drug targets for various fibrotic indications, including IPF. The gene discussed is LOX; the disease is idiopathic pulmonary fibrosis.